(Oslo, Norway, 27 January 2017) Bionor Pharma AS, a wholly owned subsidiary of Solon Eiendom ASA (OSE:SOLON) announces today that the Research Council of Norway (RCN) through its BIA Program (Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 10.3 million to partially fund an exploratory Phase I/II trial of Vacc-4x in combination with an immune regulating agent and a neutralizing antibody.

Bionor's strategy is to maintain value of the existing IP property related to Vacc-4x in combination with other medicines in order to significantly contribute to a functional HIV cure, and has, as a first step, adopted a 'Shock & Kill' clinical strategy employing Vacc-4x ('Kill') as a core treatment in combination with a latency reversing agent ('Shock'). Bionor anticipates that an immune regulating agent will also be needed as part of a triple regimen combination treatment, to achieve functional cure.

The aim of the project is to carry out a phase I/II clinical study in HIV positive participants, sequentially combining Vacc-4x with a broadly neutralizing antibody (bNab), to determine safety, and the effect on viral reservoirs and plasma viral load during latency reversal using romidepsin while on antiretroviral therapy.

Bionor Pharma ASA published this content on 27 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 January 2017 12:24:05 UTC.

Original documenthttp://www.bionorpharma.com/en/Media/News/2017/Financial/Bionor+granted+up+to+NOK+10.3+million+from+Research+Council+of+Norway+to+further+advance+Vacc-4x+in+.b7C_wlHIWq.ips

Public permalinkhttp://www.publicnow.com/view/7B317B87E22C59EF7FC65330047E9EFC45F5B4CE